ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2014
Rapamycin extends life and health in C57BL/6 mice.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
196 citing papers in PubMed, 3 syntheses or guidelines pooled it, 280 citations in OpenAlex.
- Interventions that prolong multidimensional healthspan in humans: a systematic review of randomized controlled trials.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Pooled it
- Rapamycin, Not Metformin, Mirrors Dietary Restriction-Driven Lifespan Extension in Vertebrates: A Meta-Analysis.Aging cell · 2025Pooled it
- Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review.Frontiers in aging · 2023Pooled it
- Vitamin C as a Potential Geroprotector: Interactions with Aging Hallmarks and Implications for Healthy Longevity.Nutrients · 2026Review
- Bench to bedside: is rapamycin headed for the docTOR?GeroScience · 2026Review
- Regulation of survival, growth, and metabolism by neuronal mTOR.GeroScience · 2026Article
- Chronic rapamycin treatment attenuates age-related motor deficits in sex-dependent manner in UM-HET3 mice.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Short-Term Severe Energy Restriction Promotes Molecular Health and Reverses Aging Signatures in Adults With Prediabetes in the PREVIEW Study.Aging cell · 2025Article
- The Complex Bidirectional Relationship Between Aging and Atherosclerosis: Mechanistic Insights and Translational Opportunities.Aging and disease · 2025Review
- Dietary methionine restriction started late in life promotes healthy aging in a sex-specific manner.Science advances · 2025Article
- Review
- Article
- Timing of TORC1 inhibition dictates Pol III involvement inLife science alliance · 2024Article
- Expert Consensus on Prevention and Treatment of Aging-Related Gonadal Dysfunction.Aging and disease · 2024Review
- Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies.Aging and disease · 2024Review
- Rapamycin does not alter bone microarchitecture or material properties quality in young-adult and aged female C57BL/6 mice.JBMR plus · 2024Article
- Geroprotector drugs and exercise: friends or foes on healthy longevity?BMC biology · 2023Review
- Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease.Signal transduction and targeted therapy · 2023Review
- Article
- Defining a longevity biotechnology company.Nature biotechnology · 2023Article
136 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 3 countries.
Funding
Abstract
Target of rapamycin inhibition by rapamycin feeding has previously been shown to extend life in genetically heterogeneous mice. To examine whether it similarly affected mouse health, we fed encapsulated rapamycin or a control diet to C57BL/6Nia mice of both sexes starting at 19 months of age. We performed a range of health assessments 6 and 12 months later. Rapamycin feeding significantly reduced mTOR activity in most but not all tissues. It also reduced total and resting metabolic rate during the light (inactive) phase of the light:dark cycle in females only but had no effect on spontaneous activity or metabolism during the dark (active) phase of either sex. Males only had less fragmented sleep when fed rapamycin, whereas stride length and rotarod performance were improved in both sexes. Survival was also improved by this late-life rapamycin feeding, and some pathological lesions were delayed. We found no adverse health consequences associated with rapamycin treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.